Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARES study of long-acting cabotegravir + rilpivirine versus continued oral antiretroviral therapy in virologically suppressed adults with HIV
PACTR202104874490818Phase 3Unknown
- Sponsor
- Joint Clinical Research Centre
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of cabotegravir and rilpivirine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Joint Clinical Research Centre. Primary endpoint: Plasma HIV-1 RNA <50 copies/mL. Status: unknown.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202104874490818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202104874490818.